Dermatology Drug Development Summit on November 03-05, 2026 in Boston, United States

The dermatology market is entering a pivotal new era. As competition intensifies across Atopic Dermatitis and Psoriasis, developers are under growing pressure to demonstrate meaningful differentiation, accelerate development timelines and identify the next generation of high-value opportunities beyond today's established targets and therapies.

The 10th Dermatology Drug Development Summit is the industry's premier forum dedicated to advancing the discovery, development, and commercialization of innovative therapies for inflammatory skin disease.

Bringing together 90+ leaders from the likes of AbbVie, Galderma, Merck, SUN Pharma, Eli Lilly, UNION Therapeutics and more, spanning discovery, translational medicine, preclinical development, clinical strategy, medical affairs, and commercial functions, the meeting provides a unique opportunity to benchmark emerging science, evaluate novel targets, and share practical lessons from across the dermatology pipeline.

This year's expanded program explores the future of dermatology innovation across Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Vitiligo, Alopecia Areata, Acne, Epidermolysis Bullosa, Prurigo Nodularis, and more.

With dedicated Discovery and Preclinical and Clinical and Commercial tracks, attendees will gain actionable insights into AI-enabled target discovery, translational de-risking, biomarker development, next-generation modalities, dosing optimization, clinical differentiation, and commercialization strategy.

Join the companies shaping the future of dermatology to discover where the next breakthrough therapies and the next major market opportunities will emerge.

URLs:
Tickets: https://go.evvnt.com/3703520-2?pid=10008
Brochure: https://go.evvnt.com/3703520-3?pid=10008

Date and Time: On Tue, 03 Nov 2026 08:00 - Thu, 05 Nov 2026 18:00

Venue Details: The Colonnade Hotel, 120 Huntington Avenue, Boston, Massachusetts, 02116, United States

Category: Conferences | Science, Health and Medicine | Pharmaceuticals

Prices:

Drug developer Pricing - 3 Day Pass: USD 4397.00,

Drug Developer Pricing - Conference Only: USD 3099.00,

Academic Pricing - 3 Day Pass: USD 3797.00,

Academic Pricing - Conference Only: USD 2699.00,

Service Provider Pricing - 3 Day Pass: USD 5397.00,

Service Provider Pricing - Conference Only: USD 3899.00

Speakers: Kumar Krishnaswamy, Scientific Director, Abbvie, Vanessa Morales-Tirado, Principal Scientist, Research, Abbvie, Suryasarathi Dasgupta, Director - Scientific and Precision Medicine Immunology, Abbvie, Lotus Mallbris, Senior Vice President - Business Unit and Immunology Leader, Eli Lily, Akanksha Mittal, Global and US Medical Affairs Leader, Galderma, Nathalie Wagner, Head Of Preclinical Pharmacology, Galderma, Lily Lee, Vice President and Head of Global Medical Strategy and Therapeutic Dermatology, Galderma, Xuqiu Lei, Senior Scientist, Discovery Immunology, Merck, Mudgal Kothekar, Vice President, Clinical Development, Sun Pharma, Patricia Giblin, Chief Scientific Officer ,Ability Biologics, Maria Akerman, Director, Global Programs, Affibody AB, Michael Jacobson, Chief Executive and Scientific Officer ,Alnivo Therapeutics, Neal Koller, Chairman of Directors and Chief Executive Officer, Alphyn Biologics, Paul Lizzul, Chief Medical Officer ,Anaptys Biosciences, Hyun Kim, Senior Vice President, Clinical Development, AOBiome, Dan Brownell, Research and Development, AOBiome, Karen McGuire, Chief Executive Officer, BioMendix, Alex Nivorozhkin, Founder, Director, C-Click, Par Nijhawan, Chief Executive Officer and Co-Founder, Edesa Biotech, Kenneth Crook, Head of Translational Medicine, Engimmune Therapeutics, Jose Trevejo, Chief Medical Officer, Enveda Biosciences, Michael Howell, Co-Founder, Galileo Biosystems, Anuj Singhal, Chief Executive Officer, Kalm therapeutics, David Howat, Chief Executive Officer, Mariposa Therapeutics, Kristie Grebe, Chief Scientific Officer, Navigator Medicines, Inc., Christoph Wulf, Vice President and Head of Commercial, Nielsen BioSciences, Apostolos Pappas, Chief Scientific Officer, Nogra Pharma, Mary Spellman, Chief Medical Officer, Panclarity, Frederick Beddingfield, Chief Executive Officer and Director, Rubedo Life Sciences, Kim Kjoller, Chief Executive Officer, UNION Therapeutics, Karl Koehler, Associate Professor and Head of Neck Surgery and Otolaryngology, Department of Dermatology, Harvard Medical School, John Armstrong, Head of Healthcare Banking, Westpark Capital, Harald Schnidar, Chief Executive Officer and President, Scarletred